Drugs / Ingavirin
Ingavirin
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02692742 | Mar 2016 → Nov 2017 | breast cancer, chemotherapy-induced toxicity, neutropenia | Myelo Therapeutics GmbH | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05216497 | Oct 2021 → Jan 2022 | COVID-19 | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT05269290 | Sep 2021 → Apr 2022 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT02644018 | Jan → May 2016 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT03191097 | Aug → Dec 2014 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT03206346 | Jan → Nov 2012 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT03189537 | Oct 2010 → Apr 2011 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06315400 | Dec 2023 → Dec 2025 | common cold, influenza | Valenta Pharm JSC | Unknown | No outcome recorded |
| Phase 4 | NCT03154515 | Jan 2010 → Apr 2014 | common cold, influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07420985 Comparator | Oct 2025 → Dec 2027 expected | influenza | Valenta Pharm JSC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-07-26 | Eckert & Ziegler Radiopharma GmbH | Regulatory Eckert & Ziegler: EMA Grants Drug Designation to EZAG Affiliate ezag.com ↗
Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) has announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 (Imidazolyl ethanamide pentandioic acid) for the treatment of Acute Radiation Syndrome (ARS). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-26 | Eckert & Ziegler Radiopharma GmbH | Eckert & Ziegler: EMA Grants Drug Designation to EZAG Affiliate ezag.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ingavirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03191097 ↗ |
| Known as | Imidazolyl Ethanamide Pentandioic Acid | “Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)” NCT03189537 ↗ |
| Known as | Ingamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297291 ↗ |
| Known as | Myelo001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02692742 ↗ |
| Known as | vitaglutam | “ingavirin (vitaglutam)” PMID 24432596 ↗ 2013 |
| Modality | Small molecule | “a small orally bioavailable molecule” NCT02692742 ↗ |
| Route | Oral | “administered orally 1 time a day regardless of the meal.” NCT02644018 ↗ |